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Abstract
Understanding the host immune response during cryptococcal meningitis (CM) is of critical
importance for the development of immunomodulatory therapies. We profiled the cerebro-
spinal fluid (CSF) immune-response in ninety patients with HIV-associated CM, and exam-
ined associations between immune phenotype and clinical outcome. CSF cytokine,
chemokine, and macrophage activation marker concentrations were assayed at disease
presentation, and associations between these parameters and microbiological and clinical
outcomes were examined using principal component analysis (PCA). PCA demonstrated a
co-correlated CSF cytokine and chemokine response consisting primarily of Th1, Th2, and
Th17-type cytokines. The presence of this CSF cytokine response was associated with evi-
dence of increased macrophage activation, more rapid clearance of Cryptococci from CSF,
and survival at 2 weeks. The key components of this protective immune-response were in-
terleukin (IL)-6 and interferon-γ, IL-4, IL-10 and IL-17 levels also made a modest positive
contribution to the PC1 score. A second component of co-correlated chemokines was iden-
tified by PCA, consisting primarily of monocyte chemotactic protein-1 (MCP-1) and macro-
phage inflammatory protein-1α (MIP-1α). High CSF chemokine concentrations were
associated with low peripheral CD4 cell counts and CSF lymphocyte counts and were pre-
dictive of immune reconstitution inflammatory syndrome (IRIS). In conclusion CSF cytokine
and chemokine profiles predict risk of early mortality and IRIS in HIV-associated CM. We
speculate that the presence of even minimal Cryptococcus-specific Th1-type CD4+ T-cell
responses lead to increased recruitment of circulating lymphocytes and monocytes into the
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central nervous system (CNS), more effective activation of CNS macrophages and micro-
glial cells, and faster organism clearance; while high CNS chemokine levels may predis-
pose to over recruitment or inappropriate recruitment of immune cells to the CNS and IRIS
following peripheral immune reconstitution with ART. These results provide a rational basis
for future studies of immune modulation in CM, and demonstrate the potential of baseline
immune profiling to identify CM patients most at risk of mortality and subsequent IRIS.
Author Summary
Cryptococcal meningitis is a severe opportunistic infection, estimated to kill several hun-
dred thousand HIV-infected individuals each year. One of the factors contributing to this
high death toll is the inadequacy of antifungal treatments. As few novel antifungal drugs
are being developed, several groups have started to investigate the potential of immune
modulation, with treatments designed to change the patient’s immune response to infec-
tion. However, our understanding of the immune response to cryptococcal infection in
HIV-infected patients, and how these responses impact on clinical outcomes, is limited. In
this study, we took advantage of the fact that we can sample cerebrospinal fluid (CSF)
from the site of the infection in patients when they develop cryptococcal meningitis. We
undertook a detailed analysis measuring levels of immune response parameters in the CSF
of these patients, and demonstrated that there were several distinct components of the im-
mune response. Variations in these responses were associated with both the rate at which
patients cleared their infection during treatment, and with mortality. Our results provide a
basis for the development of future immunomodulatory therapies, and may allow identifi-
cation of patients most at risk of dying, enabling more intensive treatments to be given to
those at highest risk.
Introduction
Cryptococcal meningitis (CM) is a leading cause of mortality in HIV-infected patients in low-
resource settings [1, 2]. Current treatments for CM are inadequate, with high associated mor-
tality [3–5], and high incidence of immune reconstitution inflammatory syndrome (IRIS)
amongst those who survive and start antiretroviral therapy (ART) [6–8]. Understanding the
host immune response to cryptococcal infection is important to enable rational development
of immunomodulatory therapies, and also allow identification of patients most at risk of mor-
tality and IRIS [3, 7, 9].
Much of our understanding of the immune response to Cryptococcus is derived from
in-vitro and animal experiments. In these model systems effective immunity is dependent
on robust CD4+ T-cell immune responses, the production of Th1-type cytokines such as
interferon-γ (IFNγ), and “classical” activation of effector cells such as macrophages [10–17],
leading to killing and clearance of infection. Th17-type CD4+ T-cell responses and cytokines
appear to play a protective role [18–21], whilst Th2-type responses are associated with im-
paired control of infection and poor outcomes [16, 17, 22–26].
Human data are very limited. Epidemiological evidence clearly points to the importance of
adequate CD4+ T-cell mediated immunity in the control of cryptococcal infection [27, 28], and
experimental data suggest that the phenotype of the CD4+ T-cell response to Cryptococcus neo-
formans influences the outcome of CM [9, 29]. The importance of pro-inflammatory responses
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at the site of infection [7], and in particular IFNγ [30], for effective host immune responses to
cryptococcal infection in HIV-infected patients has been reported. Preliminary data have not
shown the Th1 / Th2 dichotomy seen in some mouse models, likely reflecting differences be-
tween carefully controlled animal models of cryptococcal infection and the complex situation
in HIV-infected patients with heterogeneous immune status and organism burden [29], and
no data are available on the role of Th17-type cytokines or the magnitude or phenotype of in-
nate effector cell activation during infection.
To characterize the immune response to Cryptococcus during HIV-associated CM we mea-
sured cytokine concentrations, chemokine concentrations, and levels of macrophage activation
markers in the cerebrospinal fluid (CSF) of ninety patients with CM enrolled in a clinical trial
investigating the utility of short-course adjuvant IFNγ therapy [3]. The phenotype of the CSF
immune response, and associations between the phenotype and disease burden at presentation,
rate of clearance of infection, 2-week mortality, and development of IRIS were examined.
Materials and Methods
Participants and procedures
Ninety HIV-positive adults (age 21 years) with a first episode of cryptococcal meningitis, di-
agnosed by CSF India ink or cryptococcal antigen testing (titres1:1024, Meridian Cryptococ-
cal Latex Agglutination System; Meridian Bioscience Inc, Cincinnati, Ohio, USA), were
enrolled sequentially between July 2007 and May 2010 into a clinical trial examining the effect
of two different schedules of short-course adjuvant interferon-γ immunotherapy on the treat-
ment of HIV-associated cryptococcal meningitis in Cape Town, South Africa [3]. The study
has been described in detail elsewhere [3]. Detailed history and clinical examination findings
were recorded at study enrolment. Lumbar punctures (LPs) with quantitative cerebrospinal
fluid (CSF) cultures were performed on days 1, 3, 7 and 14. Cryptococcal clearance (early fun-
gicidal activity, or EFA) was calculated as previously described [31]. All patients had CD4+-cell
counts performed at study enrollment (FACSCount; Becton Dickinson). Patients were started
on antiretroviral therapy consisting of stavudine/lamivudine/efavirenz at 2 to 4 weeks post
commencement of antifungal therapy, and followed for one year. Mortality outcomes and the
occurrence of IRIS (diagnosed according to a standardized definition [32]) were recorded.
CSF cytokine analysis
CSF samples collected at day 1, 3, 7 and 14 were centrifuged, and the supernatant frozen at
-80°C for subsequent quantification of cytokine concentrations. CSF IFNγ, tumor necrosis fac-
tor-α (TNFα), interleukin (IL)-2, IL-4, IL-6, IL-8 (chemokine (C-X-C motif) ligand 8), IL-10,
IL-12p70, IL-17, IL-21, IL-22, IL-23, monocyte chemotactic protein-1 (MCP1, or chemokine
(C-C motif) ligand 2), macrophage inflammatory protein-1α (MIP1α, or chemokine (C-C
motif) ligand 3), RANTES (chemokine (C-C motif) ligand 5), granulocyte-macrophage
colony-stimulating factor (GM-CSF, or colony stimulating factor 2), and vascular endothelial
growth factor (VEGF) concentrations were measured in all patients using the Luminex multia-
nalyte platform (Luminex) and Bio-Rad cytokine kits (Bio-Rad) [30]. The macrophage activa-
tion markers soluble CD14 (sCD14) and neopterin concentrations were measured in CSF
using Bio-Rad and ELISA (ELItest Neopterin, BRAHMS Aktiengesellschaft, Hennigsdorf, Ger-
many) kits respectively. The enzymatic activity of arginase and protein concentration of sam-
ples were measured as previously described [33]. This analysis focuses solely on the baseline
assays performed prior to administration of antifungal therapy (results from subsequent time
points are shown in S1 Fig All data are available as a supplementary S1 data file).
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Statistical analysis
Data were analysed using Stata version 13.0 (StataCorp, College Station, Texas, USA), R ver-
sion 3.0.2 (R foundation for Statistical Computing), and Graphpad Prism version 6 (Graphpad
Software Inc., San Diego, California, USA). Baseline CSF cytokine and chemokine concentra-
tions were analysed using principal component analysis (PCA), a method of reducing complex
correlated datasets into a series of linear, non-correlated “principal components” (PCs) and
avoiding multiple comparisons. The first principal component accounts for as much of the var-
iability in the data as possible, and each subsequent component accounts for the highest vari-
ance possible under the constraint that it is uncorrelated with preceding components [34, 35].
For PCA, analyte concentrations were log transformed, and normalized to the mean. Associa-
tions between the PCs and CD4+-cell count, CSF lymphocyte count, baseline fungal burden,
rate of clearance of infection, and macrophage activation marker concentrations were exam-
ined using Pearson’s correlation coefficient. Associations between PCs and rate of clearance of
infection (but not variables recorded at baseline) were adjusted for treatment group. Differ-
ences in PC scores between patients who survived and died, and those who did and did not de-
velop IRIS, were examined using a linear regression model adjusting for treatment group,
CD4+-cell count, and the previously described risk factors for mortality, baseline fungal burden
and altered mental status [36]. A sensitivity analysis exploring differences in PC scores between
patients who survived and died, and those who did and did not develop IRIS, was preformed
limited to the patients in the trial control arm who did not receive adjuvant interferon-γ immu-
notherapy. For detailed analysis exploring the relationships between individual cytokines, asso-
ciations between continuous variables were explored using Pearson’s correlation coefficient
and linear regression analysis. Variables were compared across groups using Student’s t-tests,
Kruskal-Wallis tests, χ2 tests, or Fisher’s Exact tests as appropriate. Comparisons of paired
groups were made using the Wilcoxon matched pairs test. Permutation tests, with 5000 permu-
tations, were used to control the family wise-error rate (FWER) for the fifteen correlations /
partial correlations between the cytokines IL-4, IL-10, IL-17, MCP-1 and baseline and outcome
variables. Permutation tests used the max statistic for adjusting the p-values to ensure FWER
of 0.05 while allowing for the potentially strong correlations between variables. Unadjusted
p-values for those associations that maintained a FWER<0.05 across the multiple comparisons
are reported. Support vector machine (SVM) learning and decision tree analyses were used to
assess the capacity for baseline CSF cytokine measurements to predict mortality or IRIS. The
support vector machines algorithm was implemented in R v2.15.1 using the kernlab package
and ksvm function with a linear kernel (vanilladot), cost 1 and leave one out cross validation.
Decision tree classification was performed using Waikato Environment for Knowledge Analy-
sis (WEKA) v 3.6.9 using different decision tree classifiers (Alternating Decisions Tree, Simple
Cart, J48 Decision Tree and Random Forrest) with leave one out cross validation. For the pur-
poses of all analyses the two IFNγ treatment groups were considered as a single “IFNγ treated”
group. Statistical significance was defined as p0.05.
Ethics statement
The study was approved by the Human Research Ethics Committee of the University of Cape
Town and St. George’s University of London. Patients gave written informed consent for blood
and CSF samples to be used for research purposes.
Results
CSF samples were available from all 90 patients enrolled in the clinical trial. The median age
was 32 years (IQR 28–38), 44% (40) were male, and the median CD4+ cell count was 27 cells/μL
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(IQR 14–51). All patients were treated with amphotericin B 1mg/kg plus flucytosine 100mg/kg
daily for fourteen days. Twenty nine patients received adjunctive IFNγ 100μg subcutaneously
on days 1 and 3, and thirty patients received IFNγ 100μg subcutaneously thrice weekly for the
first two weeks of therapy. Mortality at 2-weeks was 16% (14). All patients were ART naïve at
study enrollment, and ART was initiated at a median of 23 days post initiation of antifungal
therapy. IRIS occurred in 14% of those who started ART (9/65), occurring a median of 60 days
post ART initiation (Table 1).
CSF cytokine and chemokine responses
Baseline CSF cytokine concentrations are shown in Fig 1. IL-12, IL-21, IL-22 and IL-23 concen-
trations were below the limit of detection in the majority of cases, and have been excluded
from subsequent analyses. Principal component analysis was used to identify co-correlated cy-
tokine and chemokine measurements that accounted for the variance across the data set. The
majority of the variance was reflected by PC1 (44%) and PC2 (17%) (Fig 2A). The component
loadings for each variable showed that the variance in PC1 was driven by positive loading
scores for the pro-inflammatory cytokines IL-6, IFNγ and the chemokine IL-8 (Fig 2B). IL4,
IL10 and IL17 levels also made positive, albeit more modest contribution to the PC1 score, sug-
gesting that Th1 (IFNγ), Th2 (IL4 and IL10) and Th17 (IL17) responses were co-correlated in
this context and confirmed by direct pairwise comparisons of each cytokine (Fig 3). The vari-
ance in PC2 was due to negative loading scores for the chemokines MCP-1, MIP-1α, and the
cytokine GM-CSF (Fig 2B). Hence PC1scores were positively correlated with the levels of
the pro-inflammatory cytokines IL-6 and IFNγ and PC2 scores were inversely correlated with
the levels of the chemokines MCP-1 and MIP-1α (Fig 2C and S2 Fig).
Table 1. Baseline characteristics of the patients.
Variable All patients (n = 90)
Age (years) 32 (28–38)
Sex (% male) 44% (40)
Abnormal mental status (%) 37% (33)
Baseline CD4 cell count (x 106/ml) 27 (14–51)
HIV viral load (copies/ml) 120,000 (28,000–300,000)
CSF lymphocyte count (x 106/L) 14 (0–72)
CSF protein (g/dL) 0.97 (0.55–1.54)
India ink +ve (%) 92% (83)
Baseline fungal burden (CFU/ml CSF) 240,000 (36,500–745,000)
2 week mortality (%)* 16% (14)
IRIS (%)*† 14% (9)
Results are median inter-quartile range (IQR) unless indicated. CFU, colony forming unit; CSF,
cerebrospinal ﬂuid; IRIS, immune reconstitution inﬂammatory syndrome.
*All patients were treated with Amphotericin B 1 mg/kg plus ﬂucytosine 100 mg/kg per day for 14 days
(“standard treatment”). 31 patients received standard treatment alone (“controls”). 29 patients received
standard treatment plus IFNγ 2 doses (100 μg days 1 and 3). 30 patients received standard treatment plus
IFNγ 6 doses (IFNγ 100 μg days 1,3,5,8,10, and 12). There were no signiﬁcant differences in either
mortality or frequency of IRIS between treatment groups [3].
†IRIS is expressed as percentage of patients who initiated antiretroviral therapy (n = 65)
doi:10.1371/journal.ppat.1004754.t001
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CSF cytokine and chemokine correlations with microbiological,
immunological, and clinical variables and outcomes in cryptococcal
meningitis
PCA indicated that co-correlated pro-inflammatory cytokines and chemokines represented by
PC1 scores, and those represented by PC2 scores function as independent variables. To assess
whether proinflammatory cytokines or chemokines were related to other clinically important
variables in cryptococcal meningitis we explored the relationship of PC1 and PC2 with periph-
eral blood CD4, CSF lymphocyte counts, markers of CSF macrophage (or resident CNS macro-
phage like cell) activation, CSF arginase activity, baseline CSF fungal burden, rate of clearance
of infection, 2-week mortality and IRIS (Table 2 and Table 3). PC1 scores showed a weak posi-
tive relationship with CD4 count and stronger relationship with CSF lymphocytes. PC2 scores
correlated with both of these variables. These suggest that low levels of both peripheral CD4
cell count and CSF lymphocyte count were associated with reduced levels of pro-inflammatory
cytokines but increased levels of the chemokines MCP-1 and MIP-1α in the CSF. Both PC1
and PC2 were also strongly positively correlated with the two soluble markers of macrophage
activation in CSF, neopterin and sCD14, however not with arginase activity (Table 2), indicat-
ing that macrophage activation was associated with robust pro-inflammatory CSF cytokine re-
sponses, and reduced chemokine expression. There were no significant associations between
arginase activity and either IFNγ, IL-10, or IL-4.
Fungal burden was negatively correlated with PC1 and PC2 indicating that patients with
high fungal burdens tended to have pauci-inflammatory CSF cytokine profiles with high MCP-
1 and MIP-1α chemokine expression, while lower fungal burdens were associated with more
robust CSF inflammatory responses and lower chemokine levels. Importantly PC1 scores
showed a positive correlation with more rapid clearance of cryptococci from the CSF (an asso-
ciation that remained significant after adjustment for treatment group), consistent with the
Fig 1. Baseline cerebrospinal fluid cytokine and chemokine concentrations in a cohort of ninety
patients with HIV-associated cryptococcal meningitis. Baseline concentrations of the thirteen cytokines
and chemokines measured and detected in the CSF of patients with HIV-associated cryptococcal meningitis
are shown. Cytokine and chemokine concentrations were log transformed to approximate normal distributions.
Filled bars are the inter-quartile range with a line at the median, with error bars to the 10th and 90th centiles. IL-
12, IL-21, IL-22 and IL-23 concentrations were below the limit of detection in the majority of cases.
doi:10.1371/journal.ppat.1004754.g001
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Fig 2. Principal component analysis scores and weightings. Figure (A) shows the variance of each of the principal component scores amongst the 90
patients studied. Figure (B) shows the proportion of variance in the dataset explained by each of the principal components. The majority of the variance in the
dataset was explained by the first two principal components, which were used to explore associations between CNS immune responses and outcome.
Contribution of each variable to the variance between patients in PC1 and PC2 is shown in the heat map. PC1 was composed primarily of pro-inflammatory
cytokines IL-6, IFNγ and the chemokine IL-8. PC2 contained a heavy negative weighting of chemokines MCP-1, MIP-1α and the cytokine GM-CSF.
Figure (C) shows the associations between PC1 and baseline CSF IL-6 concentrations, and PC2 and baseline CSFMCP-1 concentrations. See S2 Fig for
more detailed PC1 and PC2 associations.
doi:10.1371/journal.ppat.1004754.g002
Cryptococcal Meningitis Cytokine Profiles
PLOS Pathogens | DOI:10.1371/journal.ppat.1004754 April 8, 2015 7 / 17
hypothesis that robust pro-inflammatory responses contribute to fungal clearance. Also in
keeping with this observation, PC1 scores were lower in patients who had died within 2 weeks
compared to those who survived (Fig 4). This association was significant following adjustment
for treatment group, CD4 count, and the key predictors of mortality, baseline fungal burden
and altered mental status (p = 0.01). There were no significant associations between PC2 and
mortality (Fig 4).
Amongst patients who survived, PC2 but not PC1 scores, differentiated patients who devel-
oped IRIS following the initiation of ART (Fig 4). PC2 scores in patients who developed IRIS
were significantly lower than those who did not, showing that high chemokine expression at
baseline, associated with low peripheral CD4 counts and CSF lymphocyte counts, was predic-
tive of subsequent IRIS (Fig 4). The association between PC2 score and IRIS remained signifi-
cant in analyses adjusted for treatment group, CD4+-cell count, and the previously described
risk factors for mortality, baseline fungal burden and altered mental status, as described above
(p = 0.004), and in a linear regression model adjusting for treatment group and the known risk
factors for IRIS, baseline fungal burden and CSF white cell count (p = 0.004).
The largest contributor to PC2 was MCP-1, which was individually strongly negatively corre-
lated with CD4 count (r = -0.31, p = 0.004) and log10 CSF lymphocyte count (r = -0.46, p<0.001),
and associated with IRIS (baseline geometric mean CSF MCP-1 concentration 574.7 pg/ml in
Fig 3. Relationships between cerebrospinal fluid interferon-γ, IL-4, IL-10 and IL-17 concentrations, and their associations with disease severity
and outcome. Associations between baseline IL-4 (top row), IL-10 (middle row) and IL-17 concentrations (bottom row), and baseline IFNγ concentrations,
baseline fungal burden (quantitative cryptococcal culture, QCC), rate of clearance of infection (early fungicidal activity, EFA) and 2 week mortality. Best-fit
regression lines are shown with 95% confidence intervals. Box plots show the median and extend to the inter-quartile range, with whiskers denoting minimum
and maximum values. P-values derived from Student’s t-tests are shown for the mortality associations (both unadjusted and adjusted for family wise error
rate using permutation testing). All EFA and mortality associations were adjusted for treatment group. Pearson’s correlation coefficients and significance
levels were: IL-4/IFNγ r = 0.57 p<0.001, IL-4/QCC r = -0.23 p = 0.03, IL-4/EFA r = -0.21 p = 0.1. IL-10/IFNγ r = 0.64 p<0.001, IL-10/QCC r = -0.30 p = 0.005,
IL-10/EFA r = -0.15 p = 0.2. IL-17/IFNγ r = 0.47 p<0.001, IL-17/QCC r = -0.25 p = 0.02, IL-17/EFA r = -0.29 p = 0.03. These associations all remained
significant when controlling for a family wise error rate of 0.05.
doi:10.1371/journal.ppat.1004754.g003
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those not developing IRIS versus 2887.0 pg/ml in those who subsequently developed IRIS,
p = 0.005, Fig 5). These associations all remained significant when controlling for a FWER of 0.05.
A sensitivity analysis examining associations between PC scores and outcomes restricted to
the patients in the trial control arm who did not receive adjuvant interferon-γ immunotherapy
was performed. In this smaller sample, the association between PC1 and rate of clearance of in-
fection from the CSF and mortality were no longer significant (early fungicidal activity Pear-
son’s-r = -0.12, p = 0.5; mortality PC1 delta = -0.01, p = 0.9). The associations between PC2
and IRIS remained significant in both crude (p = 0.01) and adjusted analysis (p = 0.03).
Stratification of clinical outcomes by baseline CSF cytokine and
chemokine measurements
Taken together, our data suggest that multiparameter measurements of CSF cytokines and che-
mokines in patients presenting with cryptococcal meningitis may predict the risk of early mor-
tality or development of IRIS following ART. To test whether our data could be used to predict
these clinical outcomes, we employed machine-learning algorithms and leave one out cross-
Table 2. Correlations between principal component (PC) scores and baselinemicrobiological, immunological and clinical variables.
PC1 PC2
Variable Pearson’s-r p-value Pearson’s-r p-value
Baseline CD4 cell count (x106/ml) 0.26 0.02 0.34 0.001
CSF lymphocyte count (x106/L) 0.40 <0.001 0.57 <0.001
CSF Neopterin (log10pg/ml) 0.55 <0.001 0.30 0.004
CSF sCD14 (log10pg/ml) 0.52 <0.001 0.26 0.01
CSF arginase (units) 0.02 0.9
Baseline fungal burden (CFU/ml CSF) -0.23 0.03 -0.51 <0.001
Early fungicidal activity (log10CFU/ml/day)* -0.28 0.03 -0.21 0.04
*The association between PC1 score and EFA remained signiﬁcant in a linear regression model adjusted for treatment group (p = 0.03). Unadjusted
p-value = 0.01.
doi:10.1371/journal.ppat.1004754.t002
Table 3. Associations between principal component (PC) scores and outcome.
PC1 PC2
Mean (SE) Delta† p-value Mean (SE) Delta† p-value
Mortality (2 weeks)† Alive 0.09 (0.12) -0.95 0.01 0.01 (0.09) -0.05 0.8
Dead -0.49 (0.44) -0.08 (0.13)
IRIS¶ No IRIS 0.14 (0.12) -0.08 0.3 0.12 (0.09) -0.63 0.004
IRIS -0.25 (0.48) -0.75 (0.18)
†The adjusted p values shown were derived from a linear regression model adjusting for treatment group, CD4+-cell count, and the previously described
risk factors for mortality, baseline fungal burden and altered mental status. The adjusted delta is the β-coefﬁcient derived from the adjusted linear
regression model. Unadjusted p-values were 0.09 (PC1) and 0.7 (PC2).
¶The association between PC2 and IRIS remained signiﬁcant in both the linear regression model adjusting for treatment group, CD4+-cell count, and the
previously described risk factors for mortality, baseline fungal burden and altered mental status, as described above (p = 0.004), and a linear regression
model (results shown in table) adjusting for treatment group and the known risk factors for IRIS, baseline fungal burden and CSF white cell count
(p = 0.004). Unadjusted p-value = 0.001. The adjusted delta is the β-coefﬁcient derived from the adjusted linear regression model.
doi:10.1371/journal.ppat.1004754.t003
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validation to classify each patient after training on the data from all the other patients in the
study. To take advantage of high dimensional pattern recognition we used support vector ma-
chine learning; and to assess whether a minimum number of variables could classify patients
correctly, decision tree analyses was used (Table 4). Support vector machine learning (SVM)
correctly predicted mortality or survival at two weeks in 84% of patients and IRIS in 83% of pa-
tients. Using a variety of decision tree analyses, we were also able to predict mortality or surviv-
al at two weeks with 80-84% accuracy and IRIS with 78-84% accuracy.
Fig 4. Associations between baseline cerebrospinal fluid immune response profiles and clinical
outcome. Associations between baseline PC1 and PC2 scores and 2-week mortality and IRIS. The points
represent the mean values, with standard errors denoted by the error bars. The adjusted p value are shown,
derived from (in the case of mortality) a linear regression model adjusting for treatment group, CD4+-cell
count, and the previously described risk factors for mortality, baseline fungal burden and altered mental
status; and (in the case of IRIS) a linear regression model adjusting for treatment group, CD4+-cell count, and
the previously described risk factors for IRIS, baseline fungal burden and CSF white cell count.
doi:10.1371/journal.ppat.1004754.g004
Fig 5. Relationship between CSFMCP-1 concentrations and CD4 cell counts, cerebrospinal fluid lymphocyte counts, and immune reconstitution
syndrome. Associations between baseline MCP-1 concentrations and baseline CD4 cell count, concentrations, cerebrospinal fluid (CSF) lymphocyte count
and immune reconstitution syndrome (IRIS). The IRIS association was adjusted for treatment group. Best-fit regression lines are shown with 95% confidence
intervals. Box plots show the median and extend to the inter-quartile range, with whiskers denoting minimum and maximum values. These associations all
remained significant when controlling for a family wise error rate of 0.05.There was no significant difference in CSF MCP-1 concentrations between those
who survived (749.1 pg/ml) and those who died (858.4 pg/ml), p = 0.76.
doi:10.1371/journal.ppat.1004754.g005
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Discussion
The phenotype of the baseline CSF immune response in patients with HIV-associated CM was
shown to be associated with both microbiological and clinical outcomes, and predictive of sub-
sequent IRIS. For the first time we have demonstrated that more robust pro-inflammatory
CNS cytokine responses, characterized by higher levels of CSF IL-6 and IFNγ are associated
with evidence of increased markers of innate effector cell activation, and, in keeping with previ-
ous reports [30], more effective control of fungal burden, faster clearance of infection during
treatment, and survival. These findings are consistent with animal model data demonstrating
the importance of pro-inflammatory CNS cytokine responses [13, 37, 38] and microglial cell
activation [38, 39] in response to cytokines such as IFNγ for host resistance to cryptococcal in-
fection. They also support previous findings showing that higher expression of pro-inflamma-
tory cytokines such as IFNγ and TNFα by peripheral CD4+ T-cells [29], and higher levels of
IFNγ, TNFα, IL-6, and IL-8 in the CSF of patients with HIV-associated CM [30] are associated
with improved outcomes.
In keeping with animal models [12, 13, 19, 23, 40], our data suggests that the Th-17-type cy-
tokine, IL-17, plays an important role in the human CNS immune response to Cryptococcus.
IL-17 concentrations were closely correlated with IFNγ levels, and associated with rate of clear-
ance of infection and survival. Of note, IL-17 production was not observed in response to cryp-
tococcal mannoprotein stimulation of CD4+ T-cells from a subset of patients included in this
study[29], suggesting that the source of CSF IL-17 may not be Th17-type CD4+ T-cells. Other
cytokines associated with Th17-type T-cell responses, including IL-21, IL-22 and IL-23 were
not present in detectable quantities in the majority of patients studied, further supporting this
supposition. γδ+ T-cells, CD8+ T-cells, NK cells, and neutrophils are all capable of producing
the cytokine [21, 40–44], although it is not possible to determine the source of CSF IL-17 from
our data.
We found no evidence for a detrimental Th2-type response in CM patients, nor evidence
for arginase activity, which in mouse models of Cryptococcal infection is associated with alter-
native activation of effector cells [16]. Levels of the classic Th2 cytokine IL-4 correlated closely
with IFNγ concentrations, as did IL-10 concentrations, and both were associated with better
control and clearance of cryptococcal infection and lower mortality (although the mortality as-
sociation with these individual cytokines did not remain statistically significant following ad-
justment for multiple comparisons, requiring validation in future studies). Th2-type T-cell
responses, characterized by production of IL-4 and IL-13 and alternative activation of macro-
phages, are strongly associated with adverse outcomes in mouse models of cryptococcal infec-
tion [45]. Reasons for the differences between our findings and the animal models could relate
to intrinsic differences between mouse and human immune systems, particularly in the context
of advanced HIV-infection. The Th1/Th2 dichotomy described in mouse models appears less
Table 4.
Classiﬁcation tool Cross validation error (%)
Mortality IRIS
Support vector machine learning 15.56 16.9
Decision Tree analyses Alternating decision tree 20 18.5
J48 Algorithm 15.6 21.5
Simple Cart 16.7 15.4
Random Forrest 20 16.9
doi:10.1371/journal.ppat.1004754.t004
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pronounced in humans [46], and arginase production, which has been shown to be a marker of
disease severity in HIV-infected patients [47], is not well described in human macrophages,
but rather is associated with myeloid derived suppressor cells and neutrophils [47]. It also al-
most certainly reflects the fact that the patients in our study had been infected with Cryptococ-
cus for some time, and had had active CNS disease for several weeks prior to presentation [3].
Many of the mouse studies have examined local pulmonary responses during early infection,
prior to dissemination of infection, and not CSF cytokine profiles. Additionally mouse models
do not incorporate HIV-infection, or the effects of antifungal treatment. It is possible that a
Th1/Th2 dichotomy exists during early infection in humans, but is not reflected in the CSF
during the later stages of disease. Recent evidence suggests that both T-cell and macrophage
polarization are dynamic and plastic processes [46, 48], and the CSF immune responses ob-
served in the study patients likely represent a complex interaction of pro-inflammatory, com-
pensatory anti-inflammatory and tissue repair processes that develop as disease evolves.
In terms of cryptococcal IRIS, previous studies have identified poor baseline inflammatory
responses, rapid immune reconstitution from this low baseline, and a high organism or antigen
burdens as key risk factors [6]. Low peripheral CD4 counts and CSF lymphocyte counts, and
reduced levels of IFNγ, TNFα, IL-6, and IL-8 in the CSF at disease presentation have all been
associated with increased risk of subsequent IRIS [7–9, 49, 50]. Although, in our study, patients
who developed IRIS did tend to have a less inflammatory CSF cytokine response at baseline,
the more striking finding was that development of cryptococcal IRIS following ART initiation
was strongly associated with high CNS expression of the chemokines MCP-1, MIP-1α, and the
cytokine GM-CSF at initial CM presentation. This finding provides support for the findings of
Chang et al., who recently demonstrated that increased CNS expression of MCP-1 and MIP1α
at baseline were associated with subsequent IRIS, and hypothesized that CD8+ T-cell and mye-
loid cell trafficking into the CNS in response to these chemokines predisposed to aberrant im-
mune responses and excessive CNS inflammation following ART initiation [49].
In a previous study we have demonstrated that the phenotype of the peripheral CD4+ T-cell
response to Cryptococcus is associated with disease severity and outcome in HIV-associated
CM [29]. IFNγ and TNFα predominant responses were associated with increased CSF lympho-
cyte counts, higher levels of CSF cytokines including IL-17, and survival. This study builds on
these prior findings, suggesting that the presence of relatively small numbers of IFNγ and
TNFα-producing Cryptococcus-specific memory CD4+ T-cells are capable of promoting a cel-
lular infiltrate into the CNS in response to local production of chemokines such as MCP-1 and
MIP1α by microglial cells following exposure to Cryptococci. We hypothesize that these infil-
trating cells then stimulate expression of pro-inflammatory cytokines by both resident glial
cells and trafficked cells of myeloid and lymphoid lineages, leading to activation of microglial
cells and macrophages, with resultant restriction of intracellular growth of Cryptococci, result-
ing in lower fungal burdens at presentation, faster clearance on infection on treatment, and im-
proved survival. With the evolution of this protective, predominantly Th1-type inflammatory
cytokine response, compensatory parallel increases in both Th2-type cytokines such as IL-4
and regulatory cytokines such as IL-10 occur. In the absence of any effective Cryptococcus-
specific CD4 response, microglial cells and CNS macrophages are unable to effectively restrict
cryptococcal growth, leading to high organism burdens, poor clearance of infection during
treatment, and high mortality. These patients with severe immune suppression at baseline, in-
dicated by low peripheral CD4 counts and CSF lymphocyte counts, also have markedly up reg-
ulated CNS MCP-1 and MIP1α chemokine expression, which, following immune restoration
with ART, leads to an influx of inflammatory cells, excessive local inflammation, and IRIS.
Despite the prospective nature of our study, with comprehensive clinical and immunologi-
cal data, there are a number of limitations. Firstly, the cellular source of the CNS cytokine
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production is not possible to elucidate from these data. Unlike in previous smaller studies [30,
51], levels of CSF cytokines were significantly correlated with both peripheral CD4+ cell count
and CSF lymphocyte count. This may suggest that the source of these CSF cytokines is infiltrat-
ing T-cells and monocytes (which may be mistaken for lymphocytes on CSF cell counts). Alter-
natively such incoming cells may facilitate or stimulate cytokine production by resident CNS
immune cells. Interestingly a consistent and significant inverse relationship was seen between
the levels of the chemo-attractant chemokines MCP-1, MIP-1α and peripheral CD4+ cell count
and CSF lymphocyte count. This finding is consistent with existing data suggesting that che-
mokine production by glial cells and monocytes/macrophages is not significantly compro-
mised in patients with late stage HIV-infection [52], and that the poor CNS inflammatory
response observed is primarily the result of the absence of effective T-cell support. A biological
feedback loop appears to be in operation such that chemokine production is rapidly down-
regulated in the face of even minimal local lymphocyte infiltration and CD4+ T-cell help. Sec-
ondly, when exploring the correlations between baseline CSF immune parameters and fungal
burdens it is not possible to definitively attribute causality. Whilst it seems plausible that the as-
sociation between more vigorous CSF inflammatory responses and lower organism burdens
means that variation in the patient’s ability to mount an effective inflammatory response plays
a key role in determining disease severity, it is possible that very high organism burdens para-
doxically lead to down regulation of the host inflammatory responses. Finally, these data were
derived from a clinical trial comparing differing three treatment regimens leading to different
rates of fungal clearance (but not significant differences in mortality or rates of IRIS). The cyto-
kine and chemokine levels used in these analyses were all determined prior to the administra-
tion of any antifungal therapy, meaning all baseline comparisons are unaffected by treatment
group. And in all analyses relating to rate of clearance of infection, IRIS, and mortality out-
comes, adjustment for treatment group was made. In each of these cases the associations seen
in unadjusted analysis remained robust, or were strengthened following adjustment, support-
ing the validity of our findings. The sensitivity analysis restricted to the study control group
(i.e. those who did not receive adjuvant interferon-γ immunotherapy) was underpowered as a
result of the small sample size. However even in this small sample, although the mortality asso-
ciations were no longer significant, the association between PC2 and IRIS remained
statistically robust.
In conclusion, the presence of a CSF inflammatory response consisting of Th1, Th2 and
Th17 type cytokines has been shown to correlate with markers of innate effector cell activation,
more rapid clearance of infection and survival in patients with HIV-associated cryptococcal
meningitis. We did not find evidence of a dichotomous Th1/Th2 response. Rather Th1, Th2
and Th17 type cytokine concentrations correlate closely with each other, and the presence of
this combined inflammatory response is beneficial, while its absence is detrimental. Patients
with low peripheral CD4+ T-cell counts and CSF lymphocyte counts at disease presentation
had high CNS chemokine expression, and were at high risk of subsequent IRIS following
ART initiation.
Supporting Information
S1 Fig. The time course of the CSF immune response.Median chemokine and cytokine lev-
els, with error bars to 75th centile, are shown on days 1, 3, 7, and 14. No significant differences
in the change in cytokine levels between days 1 and 3 were seen in the interferon-γ treated pa-
tients compared to controls. Between day 1 and day 7 there were larger reductions in IL-6,
IL-17, RANTES and VEGF concentrations in IFNγ treated patients than controls, mirroring
the more rapid decline in fungal burden (IL-6 5861pg/ml reduction versus 1500pg/ml,
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p = 0.03; IL-17 6.3pg/ml reduction versus 2.7pg/ml, p = 0.007; RANTES 16.7pg/ml versus
11.8pg/ml, p = 0.05; and VEGF 1.1pg/ml reduction versus 0.8pg/ml increase, p = 0.03).
(TIFF)
S2 Fig. Principal component correlations. The associations between PC1 and baseline CSF
IL-6, IFNγ, and IL-8 concentrations; and PC2 and baseline CSF MCP-1, MIP-1α, and
GM-CSF concentrations.
(TIFF)
S1 Data File. A stata dataset containing raw anonymized baseline clinical data and log
transformed cytokine, chemokine, and macrophage activation marker levels from study
days 1, 3, 7, and 14 from the 90 study patients. Variables included are adjuvant treatment cat-
egory (interferon gamma administered), CD4 cell count (cells/μL), abnormal mental-status
(defined as a Glasgow Coma Score<15 or seizures), CSF lymphocyte count (x 106/L), baseline
fungal burden (quantitative cryptococcal culture, log10CFU/ml), rate of clearance of infection
(early fungicidal activity, log10CFU/ml/day), day 1 CSF opening pressure (cm H2O), mortality
at 2 weeks, antiretroviral initiation status, immune reconstitution inflammatory syndrome
(IRIS), and day 1, 3, 7, and 14 CSF levels of interferon-γ (IFNγ), tumor necrosis factor-α
(TNFα), interleukin (IL)-2, IL-4, IL-6, IL-8 (chemokine (C-X-C motif) ligand 8), IL-10, IL-
12p70, IL-17, IL-21, IL-22, IL-23, monocyte chemotactic protein-1 (MCP1, or chemokine (C-C
motif) ligand 2), macrophage inflammatory protein-1α (MIP1α, or chemokine (C-C motif)
ligand 3), RANTES (chemokine (C-C motif) ligand 5), granulocyte-macrophage colony-
stimulating factor (GM-CSF, or colony stimulating factor 2), vascular endothelial growth factor
(VEGF), soluble CD14 (sCD14) and neopterin concentrations (log10picograms/mL), and enzy-
matic activity of arginase.
(DTA)
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